Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task

Psychiatry Research

Volumn 220, Issue 1-2, 2014, Pages 125-128

  Horta de Macedo, Ligia R ^a   Zuardi, Antonio Waldo ^a   Machado de Sousa, João Paulo ^a   Chagas, Marcos Hortes N ^a   Hallak, Jaime E C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Emotion recognition; Face; Neuropeptides; Social cognition

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; OLANZAPINE; OXYTOCIN; PIPOTIAZINE; PLACEBO; RISPERIDONE; SERTRALINE; NEUROPEPTIDE;

AFFECT; ANGER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISGUST; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EMOTION; FACIAL EXPRESSION; FEAR; HAPPINESS; HUMAN; MALE; MENTAL PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SADNESS; SCHIZOPHRENIA; TASK PERFORMANCE; ADULT; NORMAL HUMAN; PERCEPTION; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; EMOTIONS; FACIAL EXPRESSION; HEALTHY VOLUNTEERS; HUMANS; MALE; NEUROPEPTIDES; OXYTOCIN; SCHIZOPHRENIA; SOCIAL PERCEPTION; TREATMENT OUTCOME;

EID: 84908219694     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.07.082     Document Type: Article

References (29)

1. Averbeck B.B., Bobin T., Evans S., Shergill S.S. Emotion recognition and oxytocin in patients with schizophrenia. Psychological Medicine 2011, 11:1-8.
2. Bakermans-Kranenburg M.J., van IJzendoorn M.H. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Translational Psychiatry 2013, 3:e258.
3. Baumgartner T., Heinrichs M., Vonlantner A., Fishbauer U., Fehr E. Oxytocin shapes the neural circuitry and trust adaptation in humans. Neuron 2008, 58:639-650.
4. Bech P., Kastrup M., Rafaelsen O.J. Mini-Compendium of rating scales for states of anxiety, depression, mania, and schizophrenia with corresponding DSM III syndromes. Acta Psychiatrica Scandinavia 1986, 83(S326):S7-S37.
5. Carter C.S. Sex differences in oxytocin and vasopressin: implications for autism spectrum disorders?. Behavioral Brain Research 2007, 176:38-45.
6. de Oliveira D.C.G., Zuardi A.W., Graeff F.G., Queiroz R.H.C., Crippa J.A. Anxiolytic-like effect of oxytocin in the simulated public speaking test. Journal of Psychopharmacology 2012, 26:497-504.
7. Del Ben C.M., Vilela J.A., Crippa J.A., Hallak J.E.C., Labate C.M., Zuardi A.W. Reliability of the structured clinical interview for DSM-IV - clinical versions translated into Portuguese. Revista Brasileira de Psiquiatria 2001, 23:156-159.
8. Di Simplicio M., Maussey-Chase R., Harmer C.J. Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. Journal of Psychopharmacology 2009, 23:241-248.
9. Domes G., Heinrichs M., Michel A., Berger C., Herpertz S.C. Oxytocin improves "mind-reading" in humans. Biological Psychiatry 2007, 6:731-733.
10. Edwards J., Jackson H.J., Pattinson P.E. Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review. Clinical Psychology Review 2002, 6:789-832.
11. Ekman P., Friesen W.V. Facial Emotion Encoding System 1978, Consulting Psychoanalists Press, Palo Alto, CA.
12. Feifel D., MacDonald K., Nguyen A., Cobb P., Warlan H., Galangue B., Minassian A., Becker O., Cooper J., Perry W., Lefebvre M., Gonzales J., Hadley A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenic patients. Biological Psychiatry 2010, 68:678-680.
13. Fischer-Shofty M., Shamay-Tsoory S.G., Harari H., Lekvokitz Y. The effect of intranasal administration of oxytocin on fear recognition. Neuropsychologia 2010, 48:179-184.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV) 1997, American Psychiatric Press, Washington, DC.
15. Goldman M., Marlow-O'Connor M., Torres I., Carter C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophrenia Research 2008, 98:247-255.
16. Goldman M.B., Gomes A.M., Carter C.S., Lee R. Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia. Psychopharmacology 2011, 216:101-110.
17. Guastella A.J., Mitchell P.B., Dadds M.R. Oxytocin increases gaze to the eye region of human faces. Biological Psychiatry 2008, 63:3-5.
18. Guastella A.J., Einfeld S.L., Gray K.M., Rinehart N.J., Tonge B.J., Lambert T.J., Hickie I.B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry 2010, 67:692-694.
19. Insel T.R. The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behaviour. Neuron 2010, 65:768-779.
20. Kay S.R., Fisbein A., Opler L.A.L. The positive and negative syndrome scale for schizophrenia. Schizophrenia Bulletin 1987, 13:261-276.
21. Kohler C.G., Turner T.H., Bilker W.B., Bresinger C.M., Siegel S.J., Kanes S.J., Gur R.E. Facial emotion recognition in schizophrenia: intensity effects and error pattern. American Journal of Psychiatry 2003, 160:1768-1774.
22. Kosfeld M., Heinrichs M., Zak P.J., Fischbauer U., Fehr E. Oxytocin increases trust inhumans. Nature 2005, 43:673-676.
23. Lieberman M.D., Eisenberger N.I., Crockett M.J., Tom S.M., Pfeifer J.H., Way B.M. Putting affects into words: affect labelling disrupts amygdala activity in response to affective stimuli. Psychological Sciences 2007, 18:421-428.
24. Marsh A.A., Yu H., Pine D.S., Blair R.J. Oxytocin improves emotion recognition of positive facial expressions. Psychopharmacology 2010, 209:225-232.
25. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychological Reports 1962, 10:799-812.
26. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., Leserman J., Jarskog F., Penn D.L. Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophrenia Research 2011, 132:50-53.
27. Sergi M.J., Green M.F., Widmark C., Reist C., Erhart S., Braff D.L., Kee K.S., Marder S.R., Mintz J. Social cognition and neurocognition: effects of risperidone, olanzapine and haloperidol. American Journal of Psychiatry 2007, 164:1585-1592.
28. Silver H., Bilker W., Goodman C. Impaired recognition of happy, sad and neutral expressions in schizophrenia is emotion, but not valence, specific and context dependent. Psychiatric Research 2009, 169:101-106.
29. Zhong S., Monakhov M., Mok H.P., Tong T., Lai P.S., Chew S.H., Ebstein R.P. U-shaped relations between plasma oxytocin levels and behavior in the trust-game. PLos One 2012, 7(12):e51095.